The molecular changes of these germline alterations can be targeted with drug therapy, such as belzutifan for VHL, with the resultant novel application of systemic treatment as an option for management of localized kidney cancer, as opposed to its traditional relegation to only treating metastatic disease (see Table 2 highlighting clinical trials targeting subtype-specific RCC). Here, VHL is linked to renal cell carcinoma.